Did you know?

However, Axsome’s total revenue reached $94.6M, powered by license revenue of $65.7M and royalty revenue of $0.3M thanks to a licensing agreement with U.K.-based Pharmanovia for sleep disorder ...Axsome Contact: Mark Jacobson Chief Operating Officer Axsome Therapeutics, Inc. 22 Cortlandt Street, 16th Floor New York, NY 10007 Tel: 212-332-3243 Email: [email protected] won regulatory approval for Auvelity and launched the drug in the fall of last year. Each drug could generate peak revenue of more than $1 billion, according to company and analyst forecasts.Technical Analysis for AXSM - Axsome Therapeutics, Inc. Buy or Sell? AXSM closed up 1.1 percent on Friday, September 1, 2023, on 75 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or a pulls back.846.4k shares, +14.9% compared to typical daily volume over the past 6 months. Typical daily volume is 736.6k shares over the past 6 months. Typical: 10.87 pts (14.1%) occurs 25% of the time. Extreme: 14.13 pts (18.4%) occurs 5% of the time. A summary of bullish and bearish indicators.AXSM Stock Price - Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists …Stocktwits provides real-time stock, crypto & international market data to keep you up-to-date. Find top news headlines, discover your next trade idea, share & gain insights from traders and investors from around the world, build a watchlist, buy US stocks, & create and manage your portfolio.Download the Stocktwits App and tap into the heart of the markets with millions of other investors and traders. Get instant access to professional analysis, market sentiment, trending stocks, trading ideas, new market trends, and more. Invest in stocks and ETFs commission free. FEATURES: TAP INTO THE GLOBAL VOICE OF FINANCE …Axsome Therapeutics, Inc. (AXSM) NasdaqGM - NasdaqGM Real Time Price. Currency in USD Follow 2W 10W 9M 70.19 -0.37 (-0.52%) At close: 04:00PM EDT 68.60 -1.59 (-2.27%)At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.Axsome Therapeutics Inc (AXSM) sentiment score, message volume, participation score and buzz level Advertisement 3rd Party Ad. Not an offer or recommendation by Stocktwits. See disclosure here or remove ads. AXSM Axsome Therapeutics Inc 10,961 Watch Alerts $66.51 $3.68 (5.24%) Today $68.08 1.57 (2.36%) Pre-Market About Feed News Sentiment EarningsAXSM. Firstly, I am a long on this stock and have been hold for only about 2 years. This was my second stock purchase and loved the company. AXS-05 - Wellbutrin + DM - NDA filing update late March/early April? — for MDD — for Alzheimer’s agitation — smoking cessation. Personally, I get seasonal depression and Wellbutrin is the ...AXSM Stock Price - Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists ... Not an offer or recommendation by Stocktwits.Axsome Therapeutics, Inc. NDA resubmission of AXS-07 for treatment of patients with migraine expected 2nd half 2023 after FDA meeting determined that CMC issues are the only things that need to be ...Axsome Therapeutics, Inc. Common Stock (AXSM) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets.Axsome Therapeutics (AXSM 1.40%), a newly minted commercial-stage biopharma, is set for a strong session today. Specifically, the company's shares are up by a whopping 52% in pre-market trading ...We are committed to developing products that meaningfully improve the lives of patients. Axsome is developing innovative treatments including AXS-05, AXS-07, AXS-12, and AXS‑14. learn about our pipeline. Axsome focuses on CNS conditions including depression, Alzheimer's disease agitation, migraine, narcolepsy and fibromyalgia.Accordingly, Axsome paid Jazz $53M in upfront payment with the corresponding high single-digit and mid-single-digit for sales in the U.S. for the currently approved indication and future expansions.The consensus estimate for Axsome Therapeutics’ full-year earnings is currently projected at ($4.01) per share. Additionally, Zacks Research provided estimates for Axsome Therapeutics’ future earnings, stating that their predicted earnings for the fourth quarter of 2023 will be ($1.41) per share and ($4.30) per share for fiscal year 2023.

07/17/23 11:57 AM Post #640 Re: #639: @georgejjl - New mid term topic $100.00 by or before Per Fidelity: BY Benzinga — 6:18 AM ET 07/17/2023 HC Wainwright & Co. analyst Raghuram Selvaraju maintains...At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.March 1, 2023 - 7:00 am. NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome’s Chief Executive Officer, will …In August, Axsome received FDA approval for its lead pipeline candidate AXS-05, with the trade name of Auvelity, for the treatment of adults with major depressive disorder (MDD), making it the ...

23 juil. 2023 ... Despite the lack of profitability, Axsome shows potential for significant ... Auvelity script counts from a table by a commenter on Stocktwits ...The FDA approves Axsome's (AXSM) Auvelity extended-release tablets for the treatment of major depressive disorder in adults. This becomes the first approved product for the company. Shares rise.StockTwits is a social media platform designed for sharing ideas between investors, traders, and entrepreneurs. The company was co-founded by Howard Lindzon and Soren Macbeth in 2009. The company received the first Shorty Award in the 2008 finance category. Time magazine listed the company as one of its 2010 "50 best websites." The company ……

Reader Q&A - also see RECOMMENDED ARTICLES & FAQs. Axsome Therapeutics Inc (AXSM) Stock Price Today,. Possible cause: Oct 12, 2023 · 11 analysts have issued 1 year price objectives for Axsome Therapeut.